The lead indication for our APEX technology provides an example of its power and potential
Alzheimer’s disease is among the most prevalent illnesses worldwide. It currently impacts 60% to 80% of the 50 million patients globally who are suffering from dementia. The number of people with the disease is expected to grow to 152 million by 2050, with 10 million new cases anticipated per year. Diagnosis and treatment for the disease are hindered by a lack of accessible and reliable diagnostics.
Early detection of Alzheimer’s disease has substantial clinical benefits and can empower proactive treatment and care decisions. The growing availability of medications developed to slow progression of this irreversible disease increases the importance of accurate and timely diagnosis and monitoring for all patients. Unfortunately, currently available diagnostic tests are associated with significant limitations that may impede early diagnosis and monitoring of disease progression.
PET imaging, the current gold standard, is expensive, often inaccessible and not scalable.
Molecular diagnostics use cerebrospinal fluid (CSF) obtained through painful, expensive and invasive procedures.
Cognitive behavioral assessment is subjective and unreliable, and can’t distinguish early stages of disease.
The prevalence of Alzheimer’s disease, combined with the current lack of reliable diagnostics, represents a total addressable market of at least $10 billion per year.
Due largely to these diagnostic limitations, 50% of individuals with Alzheimer’s disease never receive a referral to a neurologist or memory care specialist. Additionally, by the time it’s detected, the disease has often progressed to the mild to moderate stage, which can limit therapeutic benefit.
As an accurate, accessible and non-invasive technology, our APEX amyloid positivity test offers the potential to provide earlier, more personalized diagnosis and treatment for individuals with Alzheimer’s disease.